AUTHORS
Anna Stengel, PhD, Torsten Haferlach, MD, PhD2, Wencke Walter, PhD3
AFFILIATIONS
1 MLL MVZ GmbH, Munich, Bavaria, Germany
2 MLL MVZ GmbH, Munich, Bavaria, Germany
3 MLL MVZ GmbH, Munich, Bavaria, Germany
ABSTRACT
Background: Double minutes (dmin) are extrachromosomal, acentric DNA elements that drive focal gene amplification. They represent a recognized cytogenetic mechanism of oncogene deregulation in hematologic malignancies, particularly in acute myeloid leukemia (AML). Dmin are classically associated with amplification (amp) of MYC, KMT2A, and MECOM; other genes are only rarely described. Thus, the molecular spectrum is still incompletely characterized, and the biological and clinical relevance of yet undefined amplified loci remains uncertain.
Aim: (i) Analysis of the molecular/cytogenetic spectrum of dmin and identification of recurrent amplified genes beyond known targets (ii) Characterization of subgroups and assessment of the clinical impact of dmin-associated lesions.
Patients and methods: Retrospective analysis of 237 patients (pts) with dmin (identified by chromosome banding analysis) sent for diagnosis 10/2005 - 02/2026. Pts were classified by entity (according to WHO-HAEM5) and amplified locus (analyzed by interphase FISH). Targeted panel sequencing, analysing mutations in 40 myeloid genes was performed, as well as whole-genome and/or whole transcriptome sequencing (WGTS) of selected unclear cases. Clinical data was available for 178 pts.
Results: In total, 237 pts with dmin were identified, mainly comprising AML (n=155, 65%) and MDS (n=46, 19%). The most frequent dmin-located genes were MYC (125/237, 53%), KMT2A (48/237, 20%), and MECOM (20/237, 8%). Of note, four pts diagnosed with T-ALL harboring cryptic ABL1::NUP214 dmin were detected (median age 23 years), 11 pts had other lymphatic malignancies. 32 pts showed dmin of unknown origin, all found in AML/MDS, hence we further focused on these entities. In AML/MDS (n=201; median age 74 years; 54% female), MYC remained the most common amplified gene (52%), followed by KMT2A (20%) and MECOM (9%). WGS was performed for 24/32 pts with unclear dmin, n=6 showed amp of ETS1/11q24, (confirmed by FISH using probes for 11q23/11q24), n=8 amp of chromosome (chr) 13 material (4/8 with FLT3 amp, 4/8 with other non-recurrent genes involved), n=3 affected MN1/22q12, and n=2 SETBP1/18q12. The remaining n=5 cases showed non-recurrent genes involved or remained unclear, likely due to the small number of dmin per metaphase in these pts. WTS confirmed ETS1 overexpression in n=4 pts with ETS1/11q24 dmin and SETBP1 overexpression in one patient with SETBP1/18q12 dmin. Most frequent co-mutations included TP53 (56%), TET2 (47%), U2AF1 (23%), DNMT3A (18%), and NRAS (10%). Additional cytogenetic alterations comprised complex karyotype (63%), 5q deletion (del, 54%), TP53/17p del (47%) and -7/7q del (16%). Differences were observed between dmin subgroups: while pts with MYC dmin showed a high frequency of TET2 mutations (66%) and a low abundance of complex karyotypes (46%), pts with KMT2A dmin frequently showed complex karyotypes (93%), 5q and TP53/17p del (73% and 83%, respectively) and TP53 mutations (91%). By contrast, MECOM dmin were associated with 7/7q del (56%) and U2AF1 mutations (56%). Interestingly, cases with ETS1/11q24 amp had a unique genetic profile with frequent 5q del (100%) and SF3B1 mutations (83%). Further, all pts with chr 13 dmin had a complex karyotype, 5q del and TP53 mutations. Median overall survival (OS) of the total AML/MDS cohort was 14 months. The presence of complex karyotype, 5q del, -7/7q del, TET2 or TP53 mutation did not impact OS, while TP53 del was associated with inferior survival (16 vs 11 months (m), p=0.022). Median OS varied clearly by dmin type (KMT2A 3 m, MYC 13 m, MECOM 110 m) with the novel genes/loci identified showing intermediate OS (ETS1/11q24: 41 m, chr 13: 26 m).
Conclusions: Dmin in AML/MDS are genetically heterogeneous and define distinct subgroups characterized by specific amp targets and co-alteration patterns. WGTS enabled the identification of previously unrecognized recurrent dmin-associated loci, thereby substantially expanding the known molecular spectrum beyond established targets. The subgroups exhibit distinct genetic profiles that translate into markedly different clinical outcomes. The dismal OS of KMT2A dmin highlights the need for targeted approaches, such as menin inhibitors. Our data suggest that prognosis in dmin-positive disease is determined by the underlying genetic context and that dmin should be considered in routine cytogenetic evaluation, with complementary molecular methods used when the amplified locus is unclear.
DISCLOSURES
Anna Stengel, PhD: MLL Munich Leukemia Laboratory - Current Employment